$4995 | Single User
$7495 | Global License

Medical Affairs Reputations: Multiple Myeloma (EU5) 2016
[Report Updated: 01-11-2016]

Published by FirstWord Pharma: 01 Nov 2016 | 65330 | In Stock
Related Topics: Multiple Myeloma , Myeloma , Novartis

Introduction

Tight competition at every level of the market. Can your medical affairs team pull ahead?

We surveyed 150 EU5 oncologists and haematologists to compare the medical affairs teams for seven multiple myeloma treatments. Results show stiff competition across the pack, with two teams neck and neck for top spot and another three battling to rule the middle of the market. Where does your team rank, and what can you do to get ahead?

Find out in FirstView’s Medical Affairs Reputations: Multiple Myeloma (EU5).

Comparing 7 major myeloma treatments from Amgen, Celgene, Johnson & Johnson, and Novartis, this detailed report reveals:

How oncologists and haematologists rate your team overall, and on 12 key services.

Which services are most important.

How, and how often oncologists and haematologists want to meet with your team.

Specific suggestions for how your team can improve its services.

That’s actionable information you can use to turn your team into one that doctors rely on.

Top Takeaways

Competition at all levels: Rated for overall quality of interactions, two teams are running neck and neck for first place. Meanwhile, another three teams are competing closely in the middle of the market, and even the two last place teams are less than a point apart.

High marks for most teams: Performance scores are moderately high, while satisfaction scores tend to vary more. Especially for the two last place teams whose satisfaction scores on most services trail the pack.

Need for clinical information: Answers related to current use of medical affairs teams and the importance of various services suggest that doctors need actionable clinical information.

Clear areas for improvement: Doctors identified services related to information provision as needing improvement, and nearly all the surveyed teams need to improve the same two services.

Other unmet needs: More than a third of the surveyed doctors identified other ways teams can improve information provision, and a quarter of them pointed to potential “attitude” improvements.

Timing is critical: Surveyed doctors showed a clear preference for how often they’d like to be contacted, but several teams are reaching out too often, or not often enough.

Insight into Medical Affairs Teams for 9 Multiple Myeloma Treatments

Darzalex (daratumumab; Janssen Biotech)

Farydak (panobinostat; Novartis)

Imnovid (pomalidomide; Celgene)

Kyprolis (carfilzomib; Amgen)

Revlimid (lenalidomide; Celgene)

Thalidomide (thalidomide; Celgene)

Velcade (bortezomib; Johnson & Johnson)

An Expert-designed Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 7 medical affairs teams—answering important questions like:

What do doctors need?

How, and how often are they using your medical affairs team?

What services do they consider most important?

How often should you contact them? What channels are best?

Does your medical affairs team deliver?

How memorable are your team’s interactions with doctors?

How do doctors rank your team for performance and satisfaction in 12 key areas?

How does your team compare to the competition—in each area, and overall?

What needs improvement?

Are you delivering the services that are most important to doctors?

Where do you need to improve?

How can your team enhance its services?

Based on Interviews with Practicing Doctors

We surveyed 150 medical oncologists and haematologists from the EU5 (France, Italy, Germany, Spain, UK) - chosen from the largest community of validated physicians in the world.

All respondents:

Have been practicing for between 3 and 35 years

See at least 5 patients with multiple myeloma in a typical month

Devote at least 50% of their time to direct patient care

Have interacted with at least one listed product’s medical affairs team in the past 6 months.

We conducted the survey between November 1st and 4th, 2016.

MONEY BACK GUARANTEE!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Table of Contents
for Medical Affairs Reputations: Multiple Myeloma (EU5) 2016 [Report Updated: 01-11-2016]

  • 1.Objectives, Survey Methodology and Sampling, Products Included in the Survey, Executive Summary

    2.Current Status of Interactions with Different Medical Affairs Teams

    2.1 Interactions in the past 6 months with Medical Affairs teams for each product

    2.2 Current frequency of interactions with medical affair teams for each product

    3.Competitive Evaluation of Medical Affairs Teams Performance on Various Attributes

    3.1 Evaluation of overall quality of interactions with Medical Affairs teams for each product

    3.2 Attribute importance of Medical Affairs teams roles to physicians’ practice

    3.3 EdgeMap analysis – Competitive evaluation on Medical Affairs teams performance on attributes

    3.4 Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams

    3.5 Need-Gap analysis by product

    4.Preferred Interaction Media, Frequency, and Suggestions for Improvement

    4.1 Preferred interaction media and frequency, and suggestions for improvement

    5.Appendix

Additional Details

Publisher

FirstWord Pharma

Publisher Information

Reference

65330 |

Report Format

PDF

FirstWord Pharma Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Building Strong Cross-Functional Medical Affairs Teams
IntroductionCould your Medical Affairs team be better integrated for more effective cross-functional...
01 May 2015 by FirstWord Pharma USD $695 More Info
Medical Affairs Reputation (EU5): Biosimilar mAbs in Inflammatory Disorders
IntroductionBased on survey results from 150 rheumatologists, dermatologists, and gastroenterologist...
01 Feb 2015 by FirstWord Pharma USD $5,995 More Info
Physician Views: How do endocrinologists value diabetes-focused medical affairs teams – what could they be doing better?
Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
08 Dec 2014 by FirstWord Pharma USD $695 More Info
Medical Affairs Reputations in Oncology (EU5): Oncologists Rate Key Products and Companies
IntroductionAs the cancer drug market continues to face significant challenges in an environment of ...
02 Dec 2014 by FirstWord Pharma USD $3,900 More Info
Reshaping Medical Affairs: delivering value to KOLs and payers
IntroductionHistorically, the key role of Medical Affairs was supporting the initial regulatory appr...
21 Aug 2014 by FirstWord Pharma USD $695 More Info
Medical Affairs Reputations in Oncology: Oncologists Rate Key Products and Companies
IntroductionAs the oncology drug market continues to face significant road bumps in terms of develop...
14 Aug 2014 by FirstWord Pharma USD $3,900 More Info
Physician Views: How do pulmonologists value medical affairs teams – what could they be doing better?
Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
09 Jul 2014 by FirstWord Pharma USD $695 More Info
Physician Views: How do neurologists value multiple sclerosis medical affairs teams – what could they be doing better?
Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
18 Jun 2014 by FirstWord Pharma USD $695 More Info
Physician Views: How do oncologists value medical affairs teams – what could they be doing better?
Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
22 May 2014 by FirstWord Pharma USD $695 More Info
Ensuring Optimal Medical Affairs Performance: Delivering Measurable Value
IntroductionIn this era of transparency, Medical Affairs is rapidly becoming the new voice of Pharma...
01 May 2013 by FirstWord Pharma USD $695 More Info

This report is published by FirstWord Pharma

Download Free Report Summary PDF

Medical Affairs Reputations: Multiple Myeloma (EU5) 2016 [Report Updated: 01-11-2016] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...